China and US agree to extend trade tariff truce, says Li
MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of nearly $150 billion, announced today that the ADVANTAGE AF clinical trial’s second phase has demonstrated positive outcomes for patients with persistent atrial fibrillation (AF) using the FARAPULSE Pulsed Field Ablation (PFA) System. According to InvestingPro data, the company maintains strong financial health with moderate debt levels and sufficient cash flows to cover interest payments. The findings, which were presented at the PFA Live Case Summit and published in the journal Circulation, indicate that the treatment met all primary safety and efficacy endpoints. This development comes as Boston Scientific demonstrates robust revenue growth of 19.36% in the last twelve months, reflecting its continued success in bringing innovative medical solutions to market. For deeper insights into BSX’s financial performance and growth metrics, InvestingPro offers comprehensive analysis through its Pro Research Report, available for over 1,400 US stocks.
Persistent AF, a condition characterized by an abnormal and rapid heartbeat lasting over seven days, may lead to serious complications such as stroke and heart failure. The trial focused on the FARAWAVE PFA Catheter for pulmonary vein isolation and posterior wall ablation, as well as the FARAPOINT PFA Catheter for cavotricuspid isthmus ablation in treating atrial flutter.
The study reported 73.4% of patients were free from AF, atrial flutter, and atrial tachycardia after 12 months, surpassing the performance goal of 40%. Additionally, there was a low safety event rate of 2.4% with no instances of pulmonary vein stenosis or other serious complications. A significant 81.0% of participants achieved freedom from symptomatic documented AF recurrence, and 71.6% experienced virtually no atrial arrhythmia burden, which may correlate with a better quality of life.
Continuous monitoring with the LUX-Dx Insertable Cardiac Monitor System provided a detailed assessment of the patients’ cardiac rhythms post-ablation, capturing data on asymptomatic AF recurrence. Dr. Vivek Reddy, the study’s principal investigator, emphasized the importance of this monitoring for individualized patient care and supported the FARAPULSE PFA System as a safe and effective therapy for persistent AF.
The trial included 255 patients at 29 U.S. sites, with 141 also receiving CTI ablation for atrial flutter using the FARAPOINT PFA Catheter. This catheter, designed for use with the Boston Scientific OPAL HDx Mapping System, allows for precise visualization during procedures.
Boston Scientific anticipates FDA approval to expand the FARAPULSE PFA System’s labeling for persistent AF and is expecting regulatory approvals for the FARAPOINT PFA Catheter later in 2025.
The company’s commitment to advancing medical technology and improving patient health is evident in its ongoing innovation and comprehensive portfolio of devices for treating complex diseases. This press release statement is based on the positive results from the second phase of the ADVANTAGE AF study.
In other recent news, Boston Scientific has reported a strong performance for the first quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company’s EPS reached $0.75, exceeding the consensus forecast of $0.67, while revenue came in at $4.66 billion, ahead of the anticipated $4.57 billion. This robust performance has led to an upward revision of Boston Scientific’s 2025 guidance, now expecting year-over-year growth of 12-14%. Despite facing a $200 million impact from tariffs, the company plans to mitigate these effects through increased organic sales guidance and targeted discretionary spending cuts. RBC Capital Markets responded by lifting the company’s stock target to $120, maintaining an Outperform rating, while Canaccord Genuity reiterated a Buy rating with a price target of $117. Both firms highlighted Boston Scientific’s ability to navigate macroeconomic challenges and sustain growth in revenue, margins, and earnings. The company’s Electrophysiology segment, driven by Farapulse, and the Watchman device were noted as key contributors to the revenue surge. These developments reflect Boston Scientific’s strategic execution and strong market position in the MedTech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.